CLLS
Cellectis S.A.
stockNASDAQADR
cellectis is a clinical-stage biopharmaceutical company focused on developing a new generation of cancer immunotherapies based on gene-edited t-cells (ucart). by capitalizing on its 18 years of expertise in gene editing – built on its flagship talen® technology and pioneering electroporation system pulseagile – cellectis uses the power of the immune system to target and eradicate cancer cells. using its life-science-focused, pioneering genome engineering technologies, cellectis' goal is to create innovative products in multiple fields and with various target markets. cellectis is listed on the nasdaq market (ticker: clls) and on the nyse alternext market (ticker: alcls). to find out more about us, visit our website: www.cellectis.com talking about gene editing? we do it. talen® is a registered trademark owned by the cellectis group.
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 1.04 | 2026-11-02 | +3.87% | 3.308 |
| 1M | 1.26 | 2026-10-09 | -14.68% | 3.133 |
| 3M | 2.76 | 2026-08-10 | -61.05% | 3.233 |
| 6M | 3.85 | 2026-05-08 | -72.08% | 1.923 |
| 1Y | 3.55 | 2025-11-10 | -69.72% | 2.027 |
| 2Y | 1.77 | 2024-11-08 | -39.27% | — |
| 5Y | 11.21 | 2021-11-09 | -90.41% | 1.413 |
Cellectis S.A. (NASDAQ:CLLS) stock price today is $1.08, and today's volume is 27,721. CLLS is up 4.369% today. The 30 day average volume is 89,319. CLLS market cap is $108.29M with 100.73M shares outstanding.